Sign in
4

Changes in Ownership

Spyre Therapeutics, Inc. Filed Acc 0000950170-23-069455

Options or other derivatives

  • Director acquired 16,667 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Fairmount Funds Management LLC · Director

Table II: Derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2023-12-07 Grant or award : show line 1 in the form Series B Preferred Stock +16,667 $600.00 $10,000,200 16,667 I
Loading xslF345X05/ownership.xml…